Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Amivantamab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NEOpredict-EGF
- 24 Jan 2025 New trial record